LDL subspecies and lipidome change by evolocumab add-on therapy to empagliflozin in patients with type 2 diabetes: A prespecified secondary analysis of a randomized clinical trial
Abstract
BACKGROUND
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) reduce cardiovascular risk in type 2 diabetes. Whether these benefits are partly mediated by modifications in low-density lipoprotein (LDL) phenotype, beyond changes in LDL-cholesterol levels, remains unknown.
METHODS
In this prespecified analysis of the EXCEED-BHS3 randomized trial, 110 individuals with type 2 diabetes were assigned to 16 weeks of empagliflozin (E) or empagliflozin plus evolocumab (EE). Changes in LDL subspecies profiles were assessed in the full cohort, while LDL lipidomic alterations were evaluated in a randomly selected subset of 50 participants. Associations between lipidomic features and endothelial function were subsequently explored.
RESULTS
Empagliflozin monotherapy did not affect LDL cholesterol levels or LDL subfraction proportions. As expected, EE therapy reduced LDL cholesterol by 61 ± 27% (intragroup and intergroup p < 0.001) and shifted LDL subspecies composition, increasing LDL1 (+49 ± 32%), LDL2 (+22 ± 12%), and LDL5 (+27 ± 18%), while reducing LDL3 (-18 ± 9%) and LDL4 (-17 ± 6%). Lipidome profiling revealed 118 altered species with E and 189 with EE. E therapy decreased phosphatidylcholine (-59%), phosphatidylethanolamine (-67%), phosphatidylinositol (-73%), and cholesteryl esters (-20%), while increased phytosteryl esters (+33%), a marker of intestinal cholesterol absorption. EE therapy increased…
How strong is the evidence?
Evidence Hub reads this as a secondary / pooled analysis, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 110 participants or records.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.